CTOs on the Move


 
Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nanomixdx.com
  • 2121, Williams Street
    San Leandro, CA USA 94577
  • Phone: 510.428.5300

Executives

Name Title Contact Details

Similar Companies

Havas Health and You

Havas Health & You is a unique health and wellness network focused on promoting healthy living decisions across the entire health ecosystem. We believe in putting YOU – our employees, business partners, and our customers – at the center of everything we do. By understanding what you need and crafting unique solutions, we can help you stay and live well.

Canon Medical Systems

We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.

Total Joint Orthopedics

Total Joint Orthopedics (TJO) makes high-quality, efficient implants for hip and knee replacement. Our streamlined instrumentation is intuitive and easy to use for reproducible results.

SSCI

SSCI is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.